Key result
SF36, PROMIS, LupusQoL and LIT had the strongest evidence for acceptable measurement properties in SLE, though sensitivity to longitudinal change was generally poor to moderate across measures.
Why the study?
What are the measurement properties and responsiveness of health-related quality of life (HRQoL) measures used in adult SLE clinical trials?
Systematic Review (n=51)
What are the measurement properties and responsiveness of health-related quality of life (HRQoL) measures used in adult SLE clinical trials?
This review identifies SF36, PROMIS, LupusQoL, and LIT as having the strongest evidence for acceptable measurement properties in SLE, advocating for broader use of SLE-specific HRQoL measures in RCTs.
Answers are grounded in this paper and cite their sources.
Favors SF36, PROMIS, LupusQoL, and LIT for SLE trials; extends validation evidence while highlighting moderate longitudinal responsiveness.
Inclusion of patient-reported outcomes is important in SLE clinical trials as they allow capture of the benefits of a proposed intervention in areas deemed pertinent by patients. We aimed to compare the measurement properties of health-related quality of life (HRQoL) measures used in adults with SLE and to evaluate their responsiveness to interventions in randomised controlled trials (RCTs). A systematic review was undertaken using full original papers in English identified from three databases: MEDLINE, EMBASE and PubMed. Studies describing the validation of HRQoL measures in English-speaking adult patients with SLE and SLE drug RCTs that used an HRQoL measure were retrieved. Twenty-five validation papers and 26 RCTs were included in the indepth review evaluating the measurement properties of 4 generic (Medical Outcomes Study Short-Form 36 (SF36), Patient Reported Outcomes Measurement Information System (PROMIS) item-bank, EuroQol-5D, and Functional Assessment of Chronic Illness Therapy-Fatigue) and 3 disease-specific (Lupus Quality of Life (LupusQoL), Lupus Patient Reported Outcomes, Lupus Impact Tracker (LIT)) instruments. All measures had good convergent and discriminant validity. PROMIS provided the strongest evidence for known-group validity and reliability among generic instruments; however, data on its responsiveness have not been published. Across measures, standardised response means were generally indicative of poor-moderate sensitivity to longitudinal change. In RCTs, clinically important improvements were reported in SF36 scores from baseline; however, between-arm differences were frequently non-significant and non-important. SF36, PROMIS, LupusQoL and LIT had the strongest evidence for acceptable measurement properties, but few measures aside from the SF36 have been incorporated into clinical trials. This review highlights the importance of incorporating a broader range of SLE-specific HRQoL measures in RCTs and warrants further research that focuses on longitudinal responsiveness of newer instruments.
No takes yet. Share an insight, caveat, or question.
Izadi et al. (2018) conducted a systematic review in Systemic Lupus Erythematosus (SLE) (n=51). Health-related quality of life (HRQoL) measures was evaluated on Measurement properties and responsiveness to interventions. SF36, PROMIS, LupusQoL and LIT had the strongest evidence for acceptable measurement properties in SLE, though sensitivity to longitudinal change was generally poor to moderate across measures.
Synapse has enriched 10 related papers. Consider them for comparative context: